Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc. engages in the provision of designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with human papillomavirus. Its product pipeline includes VGX-3100, INO-3107, INO-5410, INO-4800, and PENNVAX-GP. The company was founded by David B. Weiner on June 29, 1983 and is headquartered in Plymouth Meeting, PA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Inovio progresses on RRP treatment, faces trial challenges and opportunities

Inovio Pharmaceuticals is making progress on INO-3107 and other pipeline candidates while managing financials and strategic trial design.
The company faces challenges in trial design, patient representation, and regulatory requirements but sees opportunities in market access and patient outcomes.
Overall, Inovio remains focused on advancing DNA medicine and delivering on key objectives for the benefit of patients.
Analysts' questions and executive responses indicate a thorough approach to addressing concerns and ensuring trial success.

INOVIO Pharmaceuticals reports solid Q3 performance and eyes global expansion

INOVIO Pharmaceuticals showcased financial stability, regulatory progress, and scientific advancements in Q3 2024, positioning the company for future growth.
Despite financial challenges and potential hurdles, the company's strong financial position, robust pipeline, and strategic commercial planning offer opportunities for success.
Addressing challenges like financial losses, regulatory complexities, and market competitiveness will be crucial for maximizing opportunities and achieving long-term growth.
By leveraging strengths, navigating challenges, and capitalizing on opportunities, INOVIO Pharmaceuticals aims to drive innovation, secure regulatory approvals, and capture market share.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Although vaccine plays are inherently risky, the recent robust rally in INO stock is backed by strong and compelling science.
The post The Compelling Science and the Harsh Risks Behind Inovio Pharmaceuticals appeared first on InvestorPlace.

The Compelling Science and the Harsh Risks Behind Inovio Pharmaceuticals

No news is good news for the coronavirus-focused biotech.

Why Inovio Stock Is Bouncing Back Today

Ford Motor Company

Micron Technology

Twilio

United States Steel

Twilio, Micron, Ford, Inovio and U.S. Steel were our top stock trades for Friday.

5 Top Stock Trades for Friday: TWLO, MU, F, INO, X

Inovio Pharmaceuticals, Inc. (INO) CEO Joseph Kim Presents at Cantor 2020 Global Virtual Healthcare Conference Call Transcript

A noted Inovio bear weighs in on the stock's strong showing this week.

Why Inovio Pharmaceuticals Is Losing Steam Today

Curious why INO stock jumped in recent trading? Overall optimism wasn't the only reason.

At This Point, There’s No Reason to Buy (or Dump) Inovio Pharmaceuticals Stock

Investors remain enthusiastic about comments made earlier this week by Inovio's CEO.

Why Inovio Stock Is Soaring Again Today

Inovio Pharmaceuticals teased investors on Monday that Phase 1 results were just around the corner. INO stock is still rallying.

INO Stock: Why Inovio Pharmaceuticals Is Rallying 15% Today

Shares of coronavirus stock Inovio Pharmaceuticals (INO) surged again on Tuesday. INO was up about 18% in late-morning trading and ended the trading day up 20.4% to $13.63.

Why Inovio Pharmaceuticals Skyrocketed on Tuesday

Shares of Inovio Pharmaceuticals Inc (NASDAQ: INO), which is developing a DNA vaccine for the novel coronavirus, are on a strong three-day run.

Inovio CEO Talks COVID-19 Vaccine Trials; Stock Up 20%

Bristol-Myers

CytoDyn Inc.

Gilead Sciences

Immunomedics

Mesoblast

Moderna

Novavax

Pfizer

Sorrento Therapeutics Inc

Monoclonal Antibodies: A Good Place To Be In The Time Of Covid-19 And Stock Market Bubbles

Why Inovio Pharmaceuticals Stock Is Headed Higher Today

Altimmune

Vaxart

Each of these biotech stocks has more than tripled year to date and could still have plenty of room to run.

These 3 Coronavirus Stocks Could More Than Double by the End of 2020

AstraZeneca

CureVac B.V

GlaxoSmithKline

Johnson & Johnson

Whether or not we get an 'October Surprise' from President Donald Trump, these coronavirus vaccine stocks look hot now. 
AstraZeneca (NYSE:AZN)
CureVac (NASDAQ:CVAC)
GlaxoSmithKline (NYSE:GSK)
Inovio (NASDAQ:INO)
Johnson & Johnson (NYSE:JNJ)
Moderna (NASDAQ:MRNA)
Novavax (NASDAQ:NVAX)
The post 7 Coronavirus Vaccine Stocks to Watch as Approval Nears appeared first on InvestorPlace.

7 Coronavirus Vaccine Stocks to Watch as Approval Nears

Inovio Pharmaceuticals, Inc. (INO) CEO Joseph Kim Presents at H.C.

BioNTech SE

Here are the answers to your top questions about where things stand with the development of COVID-19 vaccines.

Coronavirus Vaccine Race: 7 Key Things You'll Want to Know

INO stock has pulled back some 72% from its highs. But the fade makes sense, and even at a cheaper price the stock still looks like an avoid.

As Its Vaccine Dreams Fade, Inovio Stock Will Keep Retreating

Thermo Fisher Scientific

Inovio Pharmaceuticals Inc (NASDAQ: INO), which has had a legal tussle with its South Korean CDMO, announced Tuesday an agreement with Thermo Fisher Scientific Inc.

Inovio Analyst Says Thermo Fisher Deal 'One Solid Step' Toward COVID-19 Vaccine Commercialization

After a furious rally during the first half of the year, Inovio's stock has cooled off significantly. Can the company turn things around?

Has Inovio Stock Peaked?

Some traders will label INO stock as nothing more than a coronavirus stock. Dig deeper and you'll see that there's much more in the pipeline.

Inovio Stock Is Much More Than a Coronavirus Play

Inovio signed Thermo Fisher as a manufacturer of its coronavirus vaccine candidate, but INO stock fell; company not included among nine vaccine makers pledging safety first amid pressures.
The post Inovio Adds Thermo Fisher As A Coronavirus Vaccine Manufacturing Partner appeared first on Investor's Business Daily.

Inovio Adds Thermo Fisher As A Coronavirus Vaccine Manufacturing Partner

Shares of Inovio Pharmaceuticals Inc. INO, -2.84% gained 6.5% in premarket trading on Tuesday after the company said it had added Thermo Fisher Scientific TMO, -2.30% as a manufacturing partner for its COVID-19 vaccine candidate.

Shares of Inovio rise 6% on vaccine manufacturing deal with Thermo Fisher

How to Invest in Coronavirus Vaccine Stocks

These businesses are backed by science, and they've already got orders lined up for their experimental vaccines.

Got $5,000? Invest It in Any of These 6 Coronavirus Vaccine Stocks

Numerous well-funded coronavirus vaccines are rapidly proceeding through clinical trials. INO stock risks being left behind.

Inovio Stock Is a Longshot Covid-19 Bet

News for Inovio Pharmaceuticals Stock (INO)